ILiAD Biotechnologies closed an oversubscribed $115 million Series B to advance its whooping cough vaccine toward pivotal Phase 3 studies. The financing is sized to support late‑stage data accrual and regulatory engagement for a high‑need infectious‑disease vaccine program. Separately, Galux raised a ₩42 billion (US$29 million) Series B to scale AI‑driven antibody design and protein therapeutics discovery. Both financings signal continued investor appetite for platform innovators in vaccines and AI‑enabled biologics despite a cautious public market backdrop.